IMUX

7.0654.40%
HK

Hella Kohlhof

Co-Founder & Chief Scientific Officer

Dr. Hella Kohlhof is Co- Founder of Immunic inc. and has been Chief Scientific Officer at Immunic AG since January 01, 2017. She currently serves as managing director of Immunic Research GmbH, a German subsidiary of the Company and Constanze Investment GmbH, a German limited liability company, respectively. She studied biology in Aachen, Gothenborg (Sweden) and Munich and received her Doctorate in Biology form the Ludwig Maximiliams University of Munich (Germany). During her Ph.D. and post-doctoral position at the Institute of Clinical Molecular Biology and Tumor Genetics at the Helmholtz Centre in Munich, she worked on the normal and malignant B cell development influenced by Notch and Epstein Barr Virus mediated signaling. In 2008 she joined 4SC AG as a research scientist and group leader and established the research laboratory for translational pharmacology. She worked on 4SC’s preclinical and clinical stage projects from the oncology and immunology field, including IMU-838 and IMU-366. In early 2015, as Director of Development Projects, she took over responsibility for the complete development portfolio of 4SC AG. Dr. Kohlhof has a strong scientific background in the immunology and oncology field and is experienced in drug development, preclinical and translational pharmacology, clinical trial design and bio-marker development.

Positions